medigraphic.com
ISSN 1561-2988 (Print)

2012, Number 4

<< Back Next >>

Rev Cubana Farm 2012; 46 (4)

Use of bisphosponates in bone-related diseases

Reyes TMI, Troche CY

Language: Spanish
References: 39
Page:
PDF size: 65.41 Kb.


ABSTRACT

Bisphosphonates are drugs that help to fortify bones, reduce the risk of fractures and relieve pain in those patients who suffered metastatic cancer. These drugs generally decrease bone reabsorption when orally administered; they are also intravenously used as coadjuvant to treat certain types of cancer, hence, it is necessary to take into account the adverse effects associated to their use. This paper presented a literature review about this group of drugs for the treatment of bone-related diseases, to this end, some available databases in Google, Scirus and Medline for the last 10 years were used. It was concluded that bisphosphonates inhibit osteoclast-mediated bone reabsorption, and based on this mechanism of action, they are prescribed for the treatment of osteoporosis.


REFERENCES

  1. Saussez S, Javadian R, Hupin C, Magremanne M, Chantrain G, Loeb I, et al. Bisphosphonate-Related Osteonecrosis of the Jaw and its Associated Risk Factors: A belgian case series. The Laryngoscope [Internet] 2009 Jan [cited 2012 Feb 13];119(2):[7p.]. Available from: http://onlinelibrary.wiley.com/doi/10.1002/lary.20076

  2. Cardona Tortajada F. Osteonecrosis de los maxilares. Un efecto secundario o una complicación de los bisfosfonatos. Bol Inf Farmacoter Navar. 2009;17(5): 76-84.

  3. Licata AA. Discovery, clinical development, and therapeutic uses of bispohosphonates. Ann Pharmacother. 2005;39(4):668-77.

  4. Bifosfonatos/implantes dentales. Clínicas Propdental SL, 2011. Disponible en: http://www.propdental.com/implantes/bifosfonatos.php

  5. Molinero ÁV, Lou S, Medina E, Muñoz S, Ibáñez JA. Tratamiento de la osteoporosis con bifosfonatos: aproximaciones a nuestra realidad asistencial. Atención Primaria (España), [Internet] 2010 Jun [citado 13 Feb 2012];43(2):[4 p.] Disponible en: http://dx.doi.org/10.1016/j.aprim.2010.04.008

  6. Morton AR, Lipton A. Hypercalcemia. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical Oncology. 2nd ed. Philadelphia: Churchill Livingstone; 2000. p. 719-35.

  7. Sarantopoulos CD. Advances in the therapy of cancer pain: from novel experimental models to evidence-based treatments. SIGNA VITAE (Croacia) [Internet]. 2007 [cited 2012 Feb 13];29(Suppl 1):[19 p.] Available from: http://www.signavitae.com/articles/review-articles/32-advances-in-the-therapy-of-cancer-pain-from-novel-experimental -models-to-evidence-based-treatments

  8. Ruiz A, Hernández MA, Macías D. Principios generales del cáncer. Urgencias en oncología. 5. Metástasis óseas. Biocancer Res J [Internet]. 2004 Ene. Disponible en: http://www.biocancer.com/journal/899/5-metastasis-oseas

  9. American College of Rheumatology. Osteoporosis. 2011. [citado 2012 abril 11]. Disponible en: http://www.rheumatology.org/practice/clinical/patients /diseases_and_conditions/osteoporosis-esp.asp

  10. Cooper C. Hormone replacement therapy- 13 th IOF Advanced Training Course on Osteoporosis, International Osteosporosis Fundation, Lyon, February, 2004. p. 95-104.

  11. Torgerson DJ, Bell-Syer SE. Hormone Replacement Therapy and prevention of non-vertebral fractures: A meta-analysis of randomized trial. JAMA. 2001;285:2891-7.

  12. Delmas PD. Clinical use of SERMS and other estrogens analogs. 13 th IOF Advanced Training Course on Osteoporosis, International Osteosporosis Fundation, Lyon, February, 2004. p. 105-17.

  13. Barret-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287(7):847-57.

  14. Burckhardt P. Calcitonin and Flavonoids. 13 th IOF Advanced Training Course on Osteoporosis, International Osteosporosis Fundation, Lyon February 2004: 118-26.

  15. Fleisch H. Biphosphonates: preclinical aspects. 13 th IOF Advanced Training Course on Osteoporosis, International Osteosporosis Fundation, Lyon, February, 2004. p. 127-32.

  16. Reska AA, Rodan GA. Biphosphonate mechanism of actino. Curr Rheumatol Rep. 2003;5:65-74.

  17. Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med. 2007;36(6):319-28.

  18. Cardona Tortajada F, Sainz Gómez E, Figueredo Garmendia J. Osteonecrosis de los maxilares. Un efecto secundario o una complicación de los bisfosfonatos. Bol Inf Farmacoter Navar. 2009;17(5):76-84.

  19. Licata AA. Discovery, clinical development, and therapeutic uses of bispohosphonates. Ann Pharmacother. 2005;39(4):668-77.

  20. Petcu BE, Schung SA, Smith H. Clinical evaluation of onset of analgesia using intravenous pamidronate in metastatic bone pain. J Pain Symptom Management. 2002 Sept;24(3):281-4.

  21. Colvin L, Fallon M. Challenges in cancer management-bone pain. Eur J Cancer. 2008 May;44(8):1083-90.

  22. Bifosfonatos: una relación beneficio-riesgo dudosa. Butll GROC. 2009;22(3):9-12.

  23. Delmas PD. Clinical use of biphosphonatyes in postmenopausal osteoporosis. 13 th IOF Advanced Training Course on Osteoporosis, International Osteoporosis Fundation, Lyon, February, 2004. p. 133-50.

  24. Cranney A, Guyatt G, Krolicki N. A meta analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2001;12(2):140-51.

  25. Mc Closkey E, Selby P, De Takats D, Bernard J, Davies M, Robinson J, et al. Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone. 2001;28(3):310-5.

  26. Reginster JY, Christiansen C, Roux C, Fechtenbaum J, Rouillon A, Tou KP. Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos Int. 2001;12(3):169-77.

  27. Rizzoli R, Greenspan SL, Bone G, Schnitzer TJ, Watts NB, Adami S, et al. Two years results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 2002;17(11):1988-96.

  28. Hernández CJ, Beaupre GS, Marcus R, Carter DR. Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing. J Bone Miner Res. 2002;17(9):1662-6.

  29. Brown JP, Kendler DL, McClung M, Emkey R, Adachi J, Bolognese M. The efficacy and tolerability of risendronate, once a week, for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71(2):103-11.

  30. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-6.

  31. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83-91.

  32. Mc Clung MR, Guesens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study group. N Engl J Med. 2001;344(5):333-40.

  33. Reid IR, Brown JP, Buckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653-61.

  34. Seeman E, editor. Summaries and Critical Analyses of the Current Literature. Progress in Osteoporosis. 2010;11(1):100-31.

  35. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet [Internet] 2011 April [cited 2012 Mar 10];377(9773):[11 p.] Available from: http://dx.doi.org/10.1016/S0140-6736(10)62349-5

  36. Utilización de medicamentos. Bifosfonatos: actualización sobre su seguridad. Boletín Terapéutico Andaluz. 2010,26(2). Disponible en: http://files.sld.cu/cdfc/files/2010/09 /bifosfonatos-seguridad.pdf

  37. Yongfeng J, Ziping M, Fei D, Xie K, Fei J, inventors; Diamond Bar, CA (US). Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate. Patent Application Publication Pub. No.: US 2008/0153784 A1, United States.

  38. Gnant M, Clézardin P. Direct and indirect anticancer activity of biphosphonates: a brief review of published literature. Cancer Treat Rev. 2012 Aug;38(5):407-15.

  39. Bader R, Bastian P, Goepferich A, Roedel W, Winter G, inventors. World Intellectual Property Organization (WIPO, WO), International Bureau, Geneva. Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts. International application published under the patent cooperation treaty. International Publication Number: WO 01/85217 A1. 2001 Nov 15.




2020     |     www.medigraphic.com